i dont understand how there is much information in
Post# of 148174
what is up with those patients? why would LL underperform in that group? what was the age skew in that group?
another thing that l dont understand is why is the miTT group somehow more representative of efficacy than the non-miTT 75 patient group? most of the standard covid treatments like HCQ, tocilizumab, remdesivir dont work anyways so who cares whether or not the mitt group got those drugs? and dexamethasone has been described hypothetically not compatible with with leronlimab because the immunosuppressant blunts the effects of the immunomodulator?